Top Markets
Coin of the day
Impact Therap-b Impact Therap-b

Impact Therap-b

7630
Rang in aandelen #13207
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and... IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Aandeelprijs
$1.85
Marktkapitalisatie
$510.85M
Verandering (1 dag)
-7.37%
Verandering (1 jaar)
-
Land
CN
Handel Impact Therap-b (7630)

Categorie

Aandelsplitsingen voor Impact Therap-b (7630)
Het aandeel Impact Therap-b (symbool: 7630) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Aug 31, 2026.
Eén aandeel 7630 dat vóór Aug 31, 2026 werd gekocht, staat nu gelijk aan 0 aandelen 7630.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
4 x15
US
7 x432
US
0 -
US
2 x10000
CH
7 x226
US